{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:33:32Z","timestamp":1791232412523,"version":"4.1.0"},"reference-count":180,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRC854, B19 and A20"],"award-info":[{"award-number":["CRC854, B19 and A20"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"State of Saxony-Anhalt","award":["SI2 and SI3"],"award-info":[{"award-number":["SI2 and SI3"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Myeloproliferative neoplasms (MPNs), a group of malignant hematological disorders, occur as a consequence of somatic mutations in the hematopoietic stem cell compartment and show excessive accumulation of mature myeloid cells in the blood. A major cause of morbidity and mortality in these patients is the marked prothrombotic state leading to venous and arterial thrombosis, including myocardial infarction (MI), deep vein thrombosis (DVT), and strokes. Additionally, many MPN patients suffer from inflammation-mediated constitutional symptoms, such as fever, night sweats, fatigue, and cachexia. The chronic inflammatory syndrome in MPNs is associated with the up-regulation of various inflammatory cytokines in patients and is involved in the formation of the so-called MPN thromboinflammation. JAK2-V617F, the most prevalent mutation in MPNs, has been shown to activate a number of integrins on mature myeloid cells, including granulocytes and erythrocytes, which increase adhesion and drive venous thrombosis in murine knock-in\/out models. This review aims to shed light on the current understanding of thromboinflammation, involvement of neutrophils in the prothrombotic state, plausible molecular mechanisms triggering the process of thrombosis, and potential novel therapeutic targets for developing effective strategies to reduce the MPN disease burden.<\/jats:p>","DOI":"10.3390\/ijms23063206","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T22:09:58Z","timestamp":1647468598000},"page":"3206","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Thromboinflammation in Myeloproliferative Neoplasms (MPN)\u2014A Puzzle Still to Be Solved"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0891-5689","authenticated-orcid":false,"given":"Vikas","family":"Bhuria","sequence":"first","affiliation":[{"name":"Institute of Molecular and Clinical Immunology, Otto-von-Guericke University Magdeburg, 39120 Magdeburg, Germany"},{"name":"Health-Campus Immunology, Infectiology, and Inflammation, Medical Center, Otto-von-Guericke University Magdeburg, 39120 Magdeburg, Germany"},{"name":"Center for Health and Medical Prevention\u2014ChaMP, Otto-von-Guericke University Magdeburg, 39120 Magdeburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9653-8715","authenticated-orcid":false,"given":"Conny K.","family":"Baldauf","sequence":"additional","affiliation":[{"name":"Institute of Molecular and Clinical Immunology, Otto-von-Guericke University Magdeburg, 39120 Magdeburg, Germany"},{"name":"Health-Campus Immunology, Infectiology, and Inflammation, Medical Center, Otto-von-Guericke University Magdeburg, 39120 Magdeburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4321-7405","authenticated-orcid":false,"given":"Burkhart","family":"Schraven","sequence":"additional","affiliation":[{"name":"Institute of Molecular and Clinical Immunology, Otto-von-Guericke University Magdeburg, 39120 Magdeburg, Germany"},{"name":"Health-Campus Immunology, Infectiology, and Inflammation, Medical Center, Otto-von-Guericke University Magdeburg, 39120 Magdeburg, Germany"},{"name":"Center for Health and Medical Prevention\u2014ChaMP, Otto-von-Guericke University Magdeburg, 39120 Magdeburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Fischer","sequence":"additional","affiliation":[{"name":"Institute of Molecular and Clinical Immunology, Otto-von-Guericke University Magdeburg, 39120 Magdeburg, Germany"},{"name":"Health-Campus Immunology, Infectiology, and Inflammation, Medical Center, Otto-von-Guericke University Magdeburg, 39120 Magdeburg, Germany"},{"name":"Center for Health and Medical Prevention\u2014ChaMP, Otto-von-Guericke University Magdeburg, 39120 Magdeburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","article-title":"Proposals and Rationale for Revision of the World Health Organization Diagnostic Criteria for Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis: Recommendations from an Ad Hoc International Expert Panel","volume":"110","author":"Tefferi","year":"2007","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 Revision of the World Health Organization (WHO) Classification of Myeloid Neoplasms and Acute Leukemia: Rationale and Important Changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1182\/blood-2007-12-128454","article-title":"The Revised World Health Organization Diagnostic Criteria for Polycythemia Vera, Essential Thrombocytosis, and Primary Myelofibrosis: An Alternative Proposal","volume":"112","author":"Spivak","year":"2008","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_5","first-page":"669","article-title":"A Unique Clonal JAK2 Mutation Leading to Constitutive Signalling Causes Polycythaemia Vera","volume":"434","author":"Ugo","year":"2005","journal-title":"Med. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2008-01-131664","article-title":"MPL Mutations in Myeloproliferative Disorders: Analysis of the PT-1 Cohort","volume":"112","author":"Beer","year":"2008","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 Mutations in Myeloproliferative and Other Myeloid Disorders: A Study of 1182 Patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"McMullin, M.F., and Anderson, L.A. (2020). Aetiology of Myeloproliferative Neoplasms. Cancers, 12.","DOI":"10.3390\/cancers12071810"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41598-021-03734-6","article-title":"Incidence of Myeloid Neoplasms in Spain (2002\u20132013): A Population-Based Study of the Spanish Network of Cancer Registries","volume":"12","author":"Solans","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"470","DOI":"10.7326\/0003-4819-139-6-200309160-00009","article-title":"The Rate of Progression to Polycythemia Vera or Essential Thrombocythemia in Patients with Erythrocytosis or Thrombocytosis","volume":"139","author":"Ruggeri","year":"2003","journal-title":"Ann. Intern. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"284706","DOI":"10.1155\/2015\/284706","article-title":"Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development","volume":"2015","author":"Geyer","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"656","DOI":"10.7326\/0003-4819-123-9-199511010-00003","article-title":"Polycythemia Vera: The Natural History of 1213 Patients Followed for 20 Years. Gruppo Italiano Studio Policitemia","volume":"123","author":"Italiano","year":"1995","journal-title":"Ann. Intern. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and Prognosis among 1545 Patients with Contemporary Polycythemia Vera: An International Study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1200\/JCO.2011.36.0792","article-title":"Treatment of Polycythemia Vera with Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980","volume":"29","author":"Kiladjian","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1200\/JCO.2012.42.1925","article-title":"Patterns of Survival Among Patients With Myeloproliferative Neoplasms Diagnosed in Sweden From 1973 to 2008: A Population-Based Study","volume":"30","author":"Hultcrantz","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.blre.2014.12.002","article-title":"Mechanisms of Thrombogenesis in Polycythemia Vera","volume":"29","author":"Kroll","year":"2015","journal-title":"Blood Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s00277-016-2712-0","article-title":"Prognostic Value of CALR vs. JAK2V617F Mutations on Splenomegaly, Leukemic Transformation, Thrombosis, and Overall Survival in Patients with Primary Fibrosis: A Meta-Analysis","volume":"95","author":"Pei","year":"2016","journal-title":"Ann. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Masselli, E., Pozzi, G., Gobbi, G., Merighi, S., Gessi, S., Vitale, M., and Carubbi, C. (2020). Cytokine Profiling in Myeloproliferative Neoplasms: Overview on Phenotype Correlation, Outcome Prediction, and Role of Genetic Variants. Cells, 9.","DOI":"10.3390\/cells9092136"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1172\/JCI90312","article-title":"JAK2-V617F Promotes Venous Thrombosis through \u03921\/\u03922 Integrin Activation","volume":"128","author":"Edelmann","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.3389\/fimmu.2019.02204","article-title":"The Era of Thromboinflammation: Platelets Are Dynamic Sensors and Effector Cells During Infectious Diseases","volume":"10","author":"Guo","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"869242","DOI":"10.1155\/2015\/869242","article-title":"Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms","volume":"2015","author":"Hoermann","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Longhitano, L., Volti, G.L., Giallongo, C., Spampinato, M., Barbagallo, I., Di Rosa, M., Romano, A., Avola, R., Tibullo, D., and Palumbo, G.A. (2020). The Role of Inflammation and Inflammasome in Myeloproliferative Disease. J. Clin. Med., 9.","DOI":"10.3390\/jcm9082334"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.htct.2017.12.003","article-title":"Philadelphia-Negative Myeloproliferative Neoplasms as Disorders Marked by Cytokine Modulation","volume":"40","author":"Cacemiro","year":"2018","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Allain-Maillet, S., Bosseboeuf, A., Mennesson, N., Bosto\u00ebn, M., Dufeu, L., Choi, E.H., Cleyrat, C., Mansier, O., Lippert, E., and Le Bris, Y. (2020). Anti-Glucosylsphingosine Autoimmunity, JAK2V617F-Dependent Interleukin-1\u03b2 and JAK2V617F-Independent Cytokines in Myeloproliferative Neoplasms. Cancers, 12.","DOI":"10.3390\/cancers12092446"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/ajh.23295","article-title":"Plasma Cytokines in Polycythemia Vera: Phenotypic Correlates, Prognostic Relevance, and Comparison with Myelofibrosis","volume":"87","author":"Vaidya","year":"2012","journal-title":"Am. J. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"145293","DOI":"10.1155\/2015\/145293","article-title":"Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation","volume":"2015","author":"Hermouet","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13046-020-01776-8","article-title":"Distinct Profile of CD34+ Cells and Plasma-Derived Extracellular Vesicles from Triple-Negative Patients with Myelofibrosis Reveals Potential Markers of Aggressive Disease","volume":"40","author":"Forte","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.leukres.2012.07.009","article-title":"Molecular Profiling of Peripheral Blood Cells from Patients with Polycythemia Vera and Related Neoplasms: Identification of Deregulated Genes of Significance for Inflammation and Immune Surveillance","volume":"36","author":"Skov","year":"2012","journal-title":"Leuk. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.exphem.2014.01.006","article-title":"Cytokine Profiles in Polycythemia Vera and Essential Thrombocythemia Patients: Clinical Implications","volume":"42","author":"Pourcelot","year":"2014","journal-title":"Exp. Hematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"453020","DOI":"10.1155\/2015\/453020","article-title":"Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms","volume":"2015","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1006\/cyto.2002.1994","article-title":"Abnormal Production of Interleukin (IL)-11 and IL-8 in Polycythaemia Vera","volume":"20","author":"Hermouet","year":"2002","journal-title":"Cytokine"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e371","DOI":"10.1097\/HS9.0000000000000371","article-title":"Longitudinal Cytokine Profiling Identifies GRO-\u03b1 and EGF as Potential Biomarkers of Disease Progression in Essential Thrombocythemia","volume":"4","author":"Grinfeld","year":"2020","journal-title":"HemaSphere"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2011-04-348144","article-title":"TNF\u03b1 Facilitates Clonal Expansion of JAK2V617F Positive Cells in Myeloproliferative Neoplasms","volume":"118","author":"Fleischman","year":"2011","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.cyto.2010.07.427","article-title":"Evaluation of the Bioactive and Total Transforming Growth Factor \u03921 Levels in Primary Myelofibrosis","volume":"53","author":"Campanelli","year":"2011","journal-title":"Cytokine"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/10245330701554664","article-title":"Serum Levels, and Bone Marrow Immunohistochemical Expression of, Vascular Endothelial Growth Factor in Patients with Chronic Myeloproliferative Diseases","volume":"12","author":"Panteli","year":"2007","journal-title":"Hematology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.leukres.2006.12.024","article-title":"Global Cytokine Analysis in Myeloproliferative Disorders","volume":"31","author":"Ho","year":"2007","journal-title":"Leuk. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/jth.14759","article-title":"Cytokine and Chemokine Regulation of Venous Thromboembolism","volume":"18","author":"Najem","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Liberale, L., Holy, E.W., Akhmedov, A., Bonetti, N.R., Nietlispach, F., Matter, C.M., Mach, F., Montecucco, F., Beer, J.H., and Paneni, F. (2019). Interleukin-1\u03b2 Mediates Arterial Thrombus Formation via NET-Associated Tissue Factor. J. Clin. Med., 8.","DOI":"10.3390\/jcm8122072"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"32188","DOI":"10.1038\/srep32188","article-title":"Effects of IL-1\u03b2, IL-6 and IL-8 on Erythrocytes, Platelets and Clot Viscoelasticity","volume":"6","author":"Bester","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1002\/cncr.28857","article-title":"Comorbidities Predict Worse Prognosis in Patients with Primary Myelofibrosis","volume":"120","author":"Newberry","year":"2014","journal-title":"Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.hoc.2020.11.006","article-title":"Thrombotic, Vascular, and Bleeding Complications of the Myeloproliferative Neoplasms","volume":"35","author":"Schafer","year":"2021","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/bcj.2015.95","article-title":"Blast Transformation and Fibrotic Progression in Polycythemia Vera and Essential Thrombocythemia: A Literature Review of Incidence and Risk Factors","volume":"5","author":"Cerquozzi","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature07205","article-title":"Cancer-Related Inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.1182\/blood-2011-04-348755","article-title":"Chronic Myeloproliferative Neoplasms and Subsequent Cancer Risk: A Danish Population-Based Cohort Study","volume":"118","author":"Frederiksen","year":"2011","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/ejh.12410","article-title":"Increased Incidence of Another Cancer in Myeloproliferative Neoplasms Patients at the Time of Diagnosis","volume":"94","author":"Pettersson","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jaut.2017.06.010","article-title":"Inflammation and Myeloproliferative Neoplasms","volume":"85","author":"Lussana","year":"2017","journal-title":"J. Autoimmun."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/leu.2016.12","article-title":"Myeloproliferative Neoplasms and Inflammation: Whether to Target the Malignant Clone or the Inflammatory Process or Both Exclusion of Nonmalignant Causes of Inflammation in Patients with Suspected Mpns","volume":"30","author":"Koschmieder","year":"2016","journal-title":"Leukemia"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cytogfr.2011.10.001","article-title":"Understanding the Mechanism of IL-1\u03b2 Secretion","volume":"22","author":"Brough","year":"2011","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1182\/blood-2019-129800","article-title":"IL-1\u03b2 Secreted from Mutant Cells Carrying JAK2-V617Ffavors Early Clonal Expansion and Promotes MPN Disease Initiation and Progression","volume":"134","author":"Rai","year":"2019","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"17031","DOI":"10.1073\/pnas.0905299106","article-title":"Cell Surface-Bound IL-1\u03b1 Is an Upstream Regulator of the Senescence-Associated IL-6\/IL-8 Cytokine Network","volume":"106","author":"Orjalo","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.blre.2017.05.001","article-title":"Interleukin-1\u03b2 as Emerging Therapeutic Target in Hematological Malignancies and Potentially in Their Complications","volume":"31","author":"Arranz","year":"2017","journal-title":"Blood Rev."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"100005","DOI":"10.1016\/j.cytox.2019.100005","article-title":"Cytokines Frequently Implicated in Myeloproliferative Neoplasms","volume":"1","author":"Wang","year":"2019","journal-title":"Cytokine X"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1159\/000477253","article-title":"Clinical Correlates and Prognostic Significance of IL-8, SIL-2R, and Immunoglobulin-Free Light Chain Levels in Patients with Myelofibrosis","volume":"40","author":"Barabanshikova","year":"2017","journal-title":"Oncol. Res. Treat."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1038\/s41375-020-0827-8","article-title":"The Nlrp3 Inflammasome as a \u201cRising Star\u201d in Studies of Normal and Malignant Hematopoiesis","volume":"34","author":"Ratajczak","year":"2020","journal-title":"Leukemia"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Di Battista, V., Bochicchio, M.T., Giordano, G., Napolitano, M., and Lucchesi, A. (2021). Genetics and Pathogenetic Role of Inflammasomes in Philadelphia Negative Chronic Myeloproliferative Neoplasms: A Narrative Review. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22020561"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/s41375-019-0436-6","article-title":"NLRP3 Inflammasome Couples Purinergic Signaling with Activation of the Complement Cascade for the Optimal Release of Cells from Bone Marrow","volume":"33","author":"Ratajczak","year":"2019","journal-title":"Leukemia"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.humimm.2020.09.001","article-title":"Genetic Polymorphisms and Expression of NLRP3 Inflammasome-Related Genes Are Associated with Philadelphia Chromosome-Negative Myeloproliferative Neoplasms","volume":"81","author":"Zhou","year":"2020","journal-title":"Hum. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1182\/blood-2016-07-730556","article-title":"The NLRP3 Inflammasome Functions as a Driver of the Myelodysplastic Syndrome Phenotype","volume":"128","author":"Basiorka","year":"2016","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2018-10-844654","article-title":"The Central Role of Inflammatory Signaling in the Pathogenesis of Myelodysplastic Syndromes","volume":"133","author":"Sallman","year":"2019","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1182\/blood-2014-12-618595","article-title":"Lipocalin Produced by Myelofibrosis Cells Affects the Fate of Both Hematopoietic and Marrow Microenvironmental Cells","volume":"126","author":"Lu","year":"2015","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/10428194.2010.531413","article-title":"Increased Serum Levels of Neutrophil Gelatinase-Associated Lipocalin in Patients with Essential Thrombocythemia and Polycythemia Vera","volume":"52","author":"Allegra","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Bauvois, B., and Susin, S.A. (2018). Revisiting Neutrophil Gelatinase-Associated Lipocalin (Ngal) in Cancer: Saint or Sinner?. Cancers, 10.","DOI":"10.3390\/cancers10090336"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1172\/JCI64397","article-title":"Spleens of Myelofibrosis Patients Contain Malignant Hematopoietic Stem Cells","volume":"122","author":"Wang","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_68","first-page":"2996","article-title":"Regular Article MYELOID NEOPLASIA JAK2V617F 1 Myeloproliferative Neoplasm Clones Evoke Paracrine DNA Damage to Adjacent Normal Cells through Secretion of Lipocalin-2","volume":"124","author":"Kagoya","year":"2014","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.htct.2017.12.003","article-title":"Hematology, Transfusion and Cell Therapy Original Article Philadelphia-Negative Myeloproliferative Neoplasms as Disorders Marked by Cytokine Modulation","volume":"40","author":"Cacemiro","year":"2018","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Wong, W.J., Baltay, M., Getz, A., Fuhrman, K., Aster, J.C., Hasserjian, R.P., and Pozdnyakova, O. (2019). Gene Expression Profiling Distinguishes Prefibrotic from Overtly Fibrotic Myeloproliferative Neoplasms and Identifies Disease Subsets with Distinct Inflammatory Signatures. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0216810"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/bloodadvances.2018026450","article-title":"Defective Negative Regulation of Toll-like Receptor Signaling Leads to Excessive TNF-a in Myeloproliferative Neoplasm","volume":"3","author":"Lai","year":"2019","journal-title":"Blood Adv."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1038\/s41375-018-0131-z","article-title":"Chronic Myeloproliferative Neoplasms Autocrine Tnf Signaling Favors Malignant Cells in Myelofibrosis in a Tnfr2-Dependent Fashion","volume":"32","author":"Heaton","year":"2018","journal-title":"Leukemia"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"5349","DOI":"10.1182\/bloodadvances.2021004438","article-title":"Anti-Inflammatory Treatment in MPN: Targeting TNFR1 and TNFR2 in JAK2-V617F\u2013Induced Disease","volume":"5","author":"Baldauf","year":"2021","journal-title":"Blood Adv."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1182\/blood-2009-10-250910","article-title":"Endothelial-Derived Tissue Factor Pathway Inhibitor Regulates Arterial Thrombosis but Is Not Required for Development or Hemostasis","volume":"116","author":"White","year":"2010","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3324\/haematol.2018.195321","article-title":"Vascular Endothelial Cell Expression of JAK2 V617F Is Sufficient to Promote a Pro-Thrombotic State Due to Increased P-Selectin Expression","volume":"104","author":"Guy","year":"2019","journal-title":"Haematologica"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1055\/s-0038-1667015","article-title":"Endothelial Cells Harbouring the JAK2 V617F Mutation Display Pro-Adherent and Pro-Thrombotic Features","volume":"118","author":"Guadall","year":"2018","journal-title":"Thromb. Haemost."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/ibd.20896","article-title":"Inflammatory Bowel Disease: A Paradigm for the Link between Coagulation and Inflammation","volume":"15","author":"Yoshida","year":"2009","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"13536","DOI":"10.1038\/s41598-018-31910-8","article-title":"Platelet Activation and Prothrombotic Properties in a Mouse Model of Peritoneal Sepsis","volume":"8","author":"Bounes","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/102476","article-title":"The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms","volume":"2015","author":"Hasselbalch","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.37358\/RC.19.8.7435","article-title":"Oxidative Stress Levels, JAK2V617F Mutational Status and Thrombotic Complications in Patients with Essential Thrombocythemia","volume":"70","author":"Moisa","year":"2019","journal-title":"Rev. Chim."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.37358\/RC.19.10.7581","article-title":"Crosstalk between Oxidative Stress, Chronic Inflammation and Disease Progression in Essential Thrombocythemia","volume":"70","author":"Gaman","year":"2019","journal-title":"Rev. Chim."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3389\/fimmu.2011.00098","article-title":"Chronic Inflammation in Cancer Development","volume":"2","author":"Multhoff","year":"2012","journal-title":"Front. Immunol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/102476","article-title":"MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives","volume":"2015","author":"Hasselbalch","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","article-title":"Inflammation and Tumor Progression: Signaling Pathways and Targeted Intervention","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/sj.bjc.6604935","article-title":"Risks of Myeloid Malignancies in Patients with Autoimmune Conditions","volume":"100","author":"Anderson","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1200\/JCO.2011.34.8540","article-title":"Chronic Immune Stimulation Might Act As a Trigger for the Development of Acute Myeloid Leukemia or Myelodysplastic Syndromes","volume":"29","author":"Kristinsson","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3324\/haematol.2009.020412","article-title":"Autoimmunity and the Risk of Myeloproliferative Neoplasms","volume":"95","author":"Kristinsson","year":"2010","journal-title":"Haematologica"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.3324\/haematol.2011.055392","article-title":"The JAK2 46\/1 Haplotype: A Marker of Inappropriate Myelomonocytic Response to Cytokine Stimulation, Leading to Increased Risk of Inflammation, Myeloid Neoplasm, and Impaired Defense against Infection?","volume":"96","author":"Hermouet","year":"2011","journal-title":"Haematologica"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/ng.341","article-title":"A Common JAK2 Haplotype Confers Susceptibility to Myeloproliferative Neoplasms","volume":"41","author":"Olcaydu","year":"2009","journal-title":"Nat. Genet."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41586-021-04312-6","article-title":"Life Histories of Myeloproliferative Neoplasms Inferred from Phylogenies","volume":"602","author":"Williams","year":"2022","journal-title":"Nature"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"LBA-1","DOI":"10.1182\/blood-2020-143813","article-title":"Driver Mutation Acquisition in Utero and Childhood Followed by Lifelong Clonal Evolution Underlie Myeloproliferative Neoplasms","volume":"136","author":"Williams","year":"2020","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.stem.2021.02.001","article-title":"Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms","volume":"28","author":"Escabi","year":"2021","journal-title":"Cell Stem Cell"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Williams, N., Lee, J., Moore, L., Baxter, E.J., Hewinson, J., Dawson, K.J., Menzies, A., Godfrey, A.L., Green, A.R., and Campbell, P.J. (2020). Phylogenetic Reconstruction of Myeloproliferative Neoplasm Reveals Very Early Origins and Lifelong Evolution. bioRxiv.","DOI":"10.1101\/2020.11.09.374710"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and Safety of Low-Dose Aspirin in Polycythemia Vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1055\/s-2007-976165","article-title":"Thrombosis in Myeloproliferative Disorders: Prevalence, Prognostic Factors, and the Role of Leukocytes and JAK2V617F","volume":"33","author":"Tefferi","year":"2007","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","article-title":"Prospective Identification of High-Risk Polycythemia Vera Patients Based on JAK2 V617F Allele Burden","volume":"21","author":"Vannucchi","year":"2007","journal-title":"Leukemia"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13045-016-0242-9","article-title":"Bleeding, Thrombosis, and Anticoagulation in Myeloproliferative Neoplasms (MPN): Analysis from the German SAL-MPN-Registry","volume":"9","author":"Kaifie","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Gecht, J., Tsoukakis, I., Kricheldorf, K., Stegelmann, F., Klausmann, M., Griesshammer, M., Schulz, H., Hollburg, W., G\u00f6thert, J.R., and Sockel, K. (2021). Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms: Implications from the German Study Group for MPN Bioregistry. Cancers, 13.","DOI":"10.3390\/cancers13164086"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1182\/blood-2016-05-718114","article-title":"The Role of Leukocytes in Thrombosis","volume":"128","author":"Swystun","year":"2016","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1182\/blood-2018-05-850859","article-title":"Cooperative PSGL-1 and CXCR2 Signaling in Neutrophils Promotes Deep Vein Thrombosis in Mice","volume":"132","author":"Yago","year":"2018","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00277-007-0386-3","article-title":"Increased Platelet, Leukocyte, and Coagulation Activation in Primary Myelofibrosis","volume":"87","author":"Reverter","year":"2008","journal-title":"Ann. Hematol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1161\/CIRCRESAHA.120.316659","article-title":"Targeting Myeloid-Specific Integrin A9\u03b21 Improves Short-and Long-Term Stroke Outcomes in Murine Models with Preexisting Comorbidities by Limiting Thrombosis and Inflammation","volume":"126","author":"Dhanesha","year":"2020","journal-title":"Circ. Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.freeradbiomed.2016.01.004","article-title":"Oxidized LDL Induced Extracellular Trap Formation in Human Neutrophils via TLR-PKC-IRAK-MAPK and NADPH-Oxidase Activation","volume":"93","author":"Awasthi","year":"2016","journal-title":"Free Radic. Biol. Med."},{"key":"ref_105","first-page":"81","article-title":"Neutrophil Extracellular Traps and Its Implications in Inflammation: An Overview","volume":"8","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12964-018-0235-0","article-title":"Neutrophil Extracellular Traps Induce Aggregation of Washed Human Platelets Independently of Extracellular DNA and Histones","volume":"16","author":"Elaskalani","year":"2018","journal-title":"Cell Commun. Signal."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"eaan8292","DOI":"10.1126\/scitranslmed.aan8292","article-title":"Increased Neutrophil Extracellular Trap Formation Promotes Thrombosis in Myeloproliferative Neoplasms","volume":"10","author":"Wolach","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1182\/blood-2012-05-431288","article-title":"Dysfunction of the PI3 Kinase\/Rap1\/Integrin AIIbb3 Pathway Underlies Ex Vivo Platelet Hypoactivity in Essential Thrombocythemia","volume":"121","author":"Moore","year":"2013","journal-title":"Blood"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1182\/blood-2013-06-501452","article-title":"JAK2V617F Leads to Intrinsic Changes in Platelet Formation and Reactivity in a Knock-in Mouse Model of Essential Thrombocythemia","volume":"122","author":"Hobbs","year":"2013","journal-title":"Blood"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1182\/blood-2013-10-530832","article-title":"Hemostatic Disorders in a JAK2V617F-Driven Mouse Model of Myeloproliferative Neoplasm","volume":"124","author":"Lamrani","year":"2014","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/ajh.25713","article-title":"Platelets from Calreticulin Mutated Essential Thrombocythemia Patients Are Less Reactive than JAK2 V617F Mutated Platelets","volume":"95","author":"Hauschner","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1073\/pnas.1312148111","article-title":"JAK2V617F-Positive Endothelial Cells Contribute to Clotting Abnormalities in Myeloproliferative Neoplasms","volume":"111","author":"Etheridge","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1182\/blood-2012-07-440487","article-title":"JAK2V617F Activates Lu\/BCAM-Mediated Red Cell Adhesion in Polycythemia Vera through an EpoR-Independent Rap1\/Akt Pathway","volume":"121","author":"Cambot","year":"2013","journal-title":"Blood"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0140-6736(78)92098-6","article-title":"Vascular Occlusive Episodes and Venous H\u00e6matocrit in Primary Proliferative Polycyth\u00e6mlx","volume":"312","author":"Pearson","year":"1978","journal-title":"Lancet"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1056\/NEJMc1301262","article-title":"Treatment Target in Polycythemia Vera","volume":"368","author":"McMullin","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1182\/blood-2016-10-746479","article-title":"Elevated Hematocrit Enhances Platelet Accumulation Following Vascular Injury","volume":"129","author":"Walton","year":"2017","journal-title":"Blood"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic Basis and Molecular Pathophysiology of Classical Myeloproliferative Neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3324\/haematol.2014.113845","article-title":"Molecular Determinants of Pathogenesis and Clinical Phenotype in Myeloproliferative Neoplasms","volume":"102","author":"Grinfeld","year":"2017","journal-title":"Haematologica"},{"key":"ref_119","first-page":"287","article-title":"\u201cDo We Know Jack\u201d About JAK? A Closer Look at JAK\/STAT Signaling Pathway","volume":"1","author":"Migliaccio","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1124\/pr.119.018440","article-title":"Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution","volume":"72","author":"Bharadwaj","year":"2020","journal-title":"Pharmacol. Rev."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/s41375-018-0117-x","article-title":"Implications of STAT3 and STAT5 Signaling on Gene Regulation and Chromatin Remodeling in Hematopoietic Cancer","volume":"32","author":"Wingelhofer","year":"2018","journal-title":"Leukemia"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2017-11-814913","article-title":"Pervasive Mutations of JAK-STAT Pathway Genes in Classical Hodgkin Lymphoma","volume":"131","author":"Tiacci","year":"2018","journal-title":"Blood"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/ng.3909","article-title":"The Genomic Landscape of Pediatric and Young Adult T-Lineage Acute Lymphoblastic Leukemia","volume":"49","author":"Liu","year":"2017","journal-title":"Nat. Genet."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"100634","DOI":"10.1016\/j.blre.2019.100634","article-title":"JAKs to STATs: A Tantalizing Therapeutic Target in Acute Myeloid Leukemia","volume":"40","author":"Venugopal","year":"2020","journal-title":"Blood Rev."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"96710","DOI":"10.18632\/oncotarget.18073","article-title":"Inhibitors of the PI3K\/MTOR Pathway Prevent STAT5 Phosphorylation in JAK2V617F Mutated Cells through PP2A\/CIP2A Axis","volume":"8","author":"Bartalucci","year":"2017","journal-title":"Oncotarget"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1182\/blood-2011-01-330563","article-title":"Safety and Efficacy of Everolimus, a MTOR Inhibitor, as Single Agent in a Phase 1\/2 Study in Patients with Myelofibrosis","volume":"118","author":"Guglielmelli","year":"2011","journal-title":"Blood"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/sj.leu.2403241","article-title":"JAK\/STAT, Raf\/MEK\/ERK, PI3K\/Akt and BCR-ABL in Cell Cycle Progression and Leukemogenesis","volume":"18","author":"Steelman","year":"2004","journal-title":"Leukemia"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Guijarro-hern\u00e1ndez, A., and Vizmanos, J.L. (2021). A Broad Overview of Signaling in Ph-negative Classic Myeloproliferative Neoplasms. Cancers, 13.","DOI":"10.3390\/cancers13050984"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/ni.2456","article-title":"Neutrophil Infiltration during Inflammation Is Regulated by PILR\u03b1 via Modulation of Integrin Activation","volume":"14","author":"Wang","year":"2013","journal-title":"Nat. Immunol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/nri2986","article-title":"Immunological Synapses The Insider\u2019s Guide to Leukocyte Integrin Signalling and Function","volume":"11","author":"Hogg","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/nri1646","article-title":"Intracellular Signalling Controlling Integrin Activation in Lymphocytes","volume":"5","author":"Kinashi","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nri2156","article-title":"Getting to the Site of Inflammation: The Leukocyte Adhesion Cascade Updated","volume":"7","author":"Ley","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1083\/jcb.201303067","article-title":"JAK Tyrosine Kinases Promote Hierarchical Activation of Rho and Rap Modules of Integrin Activation","volume":"203","author":"Montresor","year":"2013","journal-title":"J. Cell Biol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/978-1-61779-166-6_18","article-title":"Rap1 and Integrin Inside-out Signaling","volume":"757","author":"Katagiri","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"ref_135","first-page":"2754","article-title":"Direct Rap1\/Talin1 Interaction Regulates Platelet and Neutrophil Integrin Activity in Mice","volume":"132","author":"Bromberger","year":"2018","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3389\/fimmu.2012.00127","article-title":"Chemokines and the Signaling Modules Regulating Integrin Affinity","volume":"3","author":"Montresor","year":"2012","journal-title":"Front. Immunol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/leu.2017.26","article-title":"JAK2-V617F Activates \u03921-Integrin-Mediated Adhesion of Granulocytes to Vascular Cell Adhesion Molecule 1","volume":"31","author":"Gupta","year":"2017","journal-title":"Leukemia"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1172\/JCI30575","article-title":"Mice Lacking the Signaling Molecule CalDAG-GEFI Represent a Model for Leukocyte Adhesion Deficiency Type III","volume":"117","author":"Bergmeier","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1002\/eji.201041196","article-title":"Rap1a Activation by CalDAG-GEFI and P38 MAPK Is Involved in E-Selectin-Dependent Slow Leukocyte Rolling","volume":"41","author":"Stadtmann","year":"2011","journal-title":"Eur. J. Immunol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1189\/jlb.0110049","article-title":"Integrin-Independent Role of CalDAG-GEFI in Neutrophil Chemotaxis","volume":"88","author":"Carbo","year":"2010","journal-title":"J. Leukoc. Biol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1002\/eji.201343994","article-title":"Ca2+-Related Signaling Events Influence TLR9-Induced IL-10 Secretion in Human B Cells","volume":"44","author":"Ziegler","year":"2014","journal-title":"Eur. J. Immunol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/cmi.2015.59","article-title":"Extracellular Calcium Elicits Feedforward Regulation of the Toll-like Receptor-Triggered Innate Immune Response","volume":"14","author":"Tang","year":"2017","journal-title":"Cell. Mol. Immunol."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Kosuru, R., and Chrzanowska, M. (2020). Molecular Sciences Integration of Rap1 and Calcium Signaling. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21051616"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1182\/bloodadvances.2017014506","article-title":"Calcium-RasGRP2-Rap1 Signaling Mediates CD38-Induced Migration of Chronic Lymphocytic Leukemia Cells","volume":"2","author":"Mele","year":"2018","journal-title":"Blood Adv."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Catani, L., Cavo, M., and Palandri, F. (2021). The Power of Extracellular Vesicles in Myeloproliferative Neoplasms: \u201cCrafting\u201d a Microenvironment That Matters. Cells, 10.","DOI":"10.3390\/cells10092316"},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"G\u0103man, M.A., Cozma, M.A., Dobric\u0103, E.C., Cre\u021boiu, S.M., G\u0103man, A.M., and Diaconu, C.C. (2021). Liquid Biopsy and Potential Liquid Biopsy-Based Biomarkers in Philadelphia-Negative Classical Myeloproliferative Neoplasms: A Systematic Review. Life, 11.","DOI":"10.3390\/life11070677"},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Fel, A., Lewandowska, A.E., Petrides, P.E., and Wi\u015bniewski, J.R. (2019). Comparison of Proteome Composition of Serum Enriched in Extracellular Vesicles Isolated from Polycythemia Vera Patients and Healthy Controls. Proteomes, 7.","DOI":"10.3390\/proteomes7020020"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"e365","DOI":"10.3324\/haematol.2016.144279","article-title":"Microparticle Phenotypes Are Associated with Driver Mutations and Distinct Thrombotic Risks in Essential Thrombocythemia","volume":"101","author":"Charpentier","year":"2016","journal-title":"Haematologica"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2003-10-3479","article-title":"Circulating Endothelial Cells as a Marker of Endothelial Damage in Allogeneic Hematopoietic Stem Cell Transplantation","volume":"103","author":"Woywodt","year":"2004","journal-title":"Blood"},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Torres, C., Fonseca, A.M., Leander, M., Matos, R., Morais, S., Campos, M., and Lima, M. (2013). Circulating Endothelial Cells in Patients with Venous Thromboembolism and Myeloproliferative Neoplasms. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0081574"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s12185-010-0596-7","article-title":"Circulating Endothelial Cells in Essential Thrombocythemia and Polycythemia Vera: Correlation with JAK2-V617F Mutational Status, Angiogenic Factors and Coagulation Activation Markers","volume":"91","author":"Wierzbowska","year":"2010","journal-title":"Int. J. Hematol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet","volume":"29","author":"Barbui","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/ajh.25303","article-title":"Polycythemia Vera and Essential Thrombocythemia: 2019 Update on Diagnosis, Risk-Stratification and Management","volume":"94","author":"Tefferi","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/ajh.26008","article-title":"Polycythemia Vera and Essential Thrombocythemia: 2021 Update on Diagnosis, Risk-Stratification and Management","volume":"95","author":"Tefferi","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.thromres.2011.09.017","article-title":"Twice Daily Aspirin to Improve Biological Aspirin Efficacy in Patients with Essential Thrombocytemia","volume":"129","author":"Dillinger","year":"2012","journal-title":"Thromb. Res."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1182\/blood-2011-06-359224","article-title":"Aspirin-Insensitive Thromboxane Biosynthesis in Essential Thrombocythemia Is Explained by Accelerated Renewal of the Drug Target","volume":"119","author":"Pascale","year":"2012","journal-title":"Blood"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"636675","DOI":"10.3389\/fonc.2020.636675","article-title":"Evaluation of Therapeutic Strategies to Reduce the Number of Thrombotic Events in Patients With Polycythemia Vera and Essential Thrombocythemia","volume":"10","author":"Tremblay","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1007\/s00277-014-2224-8","article-title":"Prophylaxis and Management of Venous Thromboembolism in Patients with Myeloproliferative Neoplasms: Consensus Statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncolo","volume":"93","author":"Kreher","year":"2014","journal-title":"Ann. Hematol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1007\/s00277-014-2152-7","article-title":"Busulfan in Patients with Polycythemia Vera or Essential Thrombocythemia Refractory or Intolerant to Hydroxyurea","volume":"93","author":"Antelo","year":"2014","journal-title":"Ann. Hematol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea Compared with Anagrelide in High-Risk Essential Thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","article-title":"Ruxolitinib for the Treatment of Inadequately Controlled Polycythaemia Vera without Splenomegaly (RESPONSE-2): A Randomised, Open-Label, Phase 3b Study","volume":"18","author":"Passamonti","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ypat.2012.11.020","article-title":"A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis","volume":"2013","author":"Signorelli","year":"2013","journal-title":"Yearb. Pathol. Lab. Med."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1056\/NEJMoa1010790","article-title":"Body-Weight-Supported Treadmill Rehabilitation after Stroke","volume":"364","author":"Duncan","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/bloodadvances.2019001158","article-title":"Ruxolitinib for the Prevention of Thrombosis in Polycythemia Vera: A Systematic Review and Meta-Analysis","volume":"4","author":"Masciulli","year":"2020","journal-title":"Blood Adv."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/MBC.0000000000000446","article-title":"The Impact of Ruxolitinib on Thrombosis in Patients with Polycythemia Vera and Myelofibrosis: A Meta-Analysis","volume":"27","author":"Samuelson","year":"2016","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1182\/blood-2015-03-635235","article-title":"Brief Report The Effect of Long-Term Ruxolitinib Treatment on JAK2p.V617F Allele Burden in Patients with Myelofibrosis","volume":"126","author":"Deininger","year":"2015","journal-title":"Blood"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.leukres.2014.06.019","article-title":"Interferon-2b Gains High Sustained Response Therapy for Advanced Essential Thrombocythemia and Polycythemia Vera with JAK2V617F Positive Mutation","volume":"38","author":"Huang","year":"2014","journal-title":"Leuk. Res."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/S2352-3026(17)30030-3","article-title":"Pegylated Interferon Alfa-2a in Patients with Essential Thrombocythaemia or Polycythaemia Vera: A Post-Hoc, Median 83 Month Follow-up of an Open-Label, Phase 2 Trial","volume":"4","author":"Masarova","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1182\/blood-2010-08-258772","article-title":"The Renaissance of Interferon Therapy for the Treatment of Myeloid Malignancies","volume":"117","author":"Kiladjian","year":"2011","journal-title":"Blood"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1182\/blood-2013-04-498956","article-title":"JAK2V617F Expression in Mice Amplifies Early Hematopoietic Cells and Gives Them a Competitive Advantage That Is Hampered by IFNa","volume":"122","author":"Hasan","year":"2013","journal-title":"Blood"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1182\/blood-2012-05-432989","article-title":"Depletion of Jak2V617F Myeloproliferative Neoplasm-Propagating Stem Cells by Interferon-\u03b1 in a Murine Model of Polycythemia Vera","volume":"121","author":"Mullally","year":"2013","journal-title":"Blood"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/leu.2008.280","article-title":"Interferon-\u03b1 Therapy in Bcr-Abl-Negative Myeloproliferative Neoplasms","volume":"22","author":"Kiladjian","year":"2008","journal-title":"Leukemia"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1200\/JCO.1986.4.2.234","article-title":"Clinical Toxicity of Interferons in Cancer Patients: A Review","volume":"4","author":"Quesada","year":"1986","journal-title":"J. Clin. Oncol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1182\/blood.2019000428","article-title":"Pegylated Interferon Alfa-2a for Polycythemia Vera or Essential Thrombocythemia Resistant or Intolerant to Hydroxyurea","volume":"134","author":"Yacoub","year":"2019","journal-title":"Blood"},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Kj\u00e6r, L., Cordua, S., Holmstr\u00f6m, M.O., Thomassen, M., Kruse, T.A., Pallisgaard, N., Larsen, T.S., De Stricker, K., Skov, V., and Hasselbalch, H.C. (2016). Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0165336"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/78412","article-title":"CD18 Trials Disappoint Again","volume":"18","author":"Dove","year":"2000","journal-title":"Nat. Biotechnol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41573-021-00284-4","article-title":"Emerging Therapeutic Opportunities for Integrin Inhibitors","volume":"21","author":"Slack","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrd.2015.10","article-title":"Integrin-Based Therapeutics: Biological Basis, Clinical Use and New Drugs","volume":"15","author":"Ley","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"15559","DOI":"10.1038\/ncomms15559","article-title":"Leukocyte Integrin Mac-1 Regulates Thrombosis via Interaction with Platelet GPIb\u03b1","volume":"8","author":"Wang","year":"2017","journal-title":"Nat. Commun."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/6\/3206\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:37:48Z","timestamp":1760135868000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/6\/3206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,16]]},"references-count":180,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["ijms23063206"],"URL":"https:\/\/doi.org\/10.3390\/ijms23063206","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,16]]}}}